Dompé Farmaceutici
This sponsor has funded 3 studies across 5 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 2679 | Finalised | SURVEILLANCE STUDY OF PHOTOCONTACT DERMATITIS LEADING TO HOSPITALIZATION IN EUROPE WITH A SPECIAL FOCUS ON TOPICAL KETOPROFEN AND OTHER TOPICAL... | Yes | No |
| 11765 | Finalised | Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and... | Yes | Yes |
| 32335 | Finalised | Observational Post-Authorisation Study of Oxervate® (Cenegermin 20 µg/ml) eye drops in the treatment of adult patients with moderate or severe... | No | Yes |
PAS by Risk Management Plan (RMP) requirement
Dompé Farmaceutici
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Dompé Farmaceutici
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Dompé Farmaceutici
5 Study countries specified are the following:
- Czechia
- France
- Greece
- Italy
- Portugal